Clinical Trial Detail

NCT ID NCT01989052
Title Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Annick Desjardins
Indications

gliosarcoma

malignant glioma

glioblastoma multiforme

Therapies

Lomustine

Carboxyamidotriazole Orotate

Age Groups: adult

No variant requirements are available.